DAFNA Capital Management LLC Makes New $904,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

DAFNA Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 522,500 shares of the company's stock, valued at approximately $904,000. DAFNA Capital Management LLC owned approximately 0.25% of Taysha Gene Therapies at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC raised its holdings in shares of Taysha Gene Therapies by 7.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock worth $34,600,000 after acquiring an additional 1,349,999 shares during the period. Vanguard Group Inc. lifted its stake in shares of Taysha Gene Therapies by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after buying an additional 641,305 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies in the 4th quarter worth about $8,650,000. Geode Capital Management LLC raised its stake in Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after purchasing an additional 9,591 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Taysha Gene Therapies by 1.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company's stock valued at $6,033,000 after buying an additional 37,844 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TSHA shares. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies has a consensus rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Stock Down 2.2%

Shares of NASDAQ TSHA traded down $0.05 during trading on Tuesday, hitting $2.27. The stock had a trading volume of 1,226,832 shares, compared to its average volume of 2,814,221. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market capitalization of $465.47 million, a PE ratio of 3.60 and a beta of 0.90. The firm has a fifty day moving average of $1.66 and a two-hundred day moving average of $1.81.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.